SCHEMBL6804497

SCHEMBL6804497

CC(=O)c1c(-c2ccsc2)sc(Cl)c1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.51
GPR35 Q9HC97 1/20 0.40
KDM4E B2RXH2 1/20 0.38
GRM6 O15303 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
MAPT P10636 2/20 0.35
USP2 O75604 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HSP90AA1 P07900 1/20 0.34
CDC7 O00311 1/20 0.34
DBF4 Q9UBU7 1/20 0.34
IKBKB O14920 2/20 0.33
ALDH1A1 P00352 2/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
PTPN1 P18031 1/20 0.33
CSNK1A1 P48729 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6809510 0.80 CSNK1A1 (0.50) KDM4EGRM6MEN1KMT2AMAPT
SCHEMBL6803591 0.80 RAB9A (0.45) KDM4EGRM6MEN1KMT2AMAPT
SCHEMBL6803372 0.80 GRM6 (0.55) KDM4EGRM6MEN1KMT2AMAPT
SCHEMBL6804787 0.78 BRD4 (0.48) BRD4GPR35KDM4EGRM6MEN1
SCHEMBL6801615 0.77 GRM6 (0.44) KDM4EGRM6KMT2AALDH1A1
SCHEMBL6803007 0.75 NPC1 (0.44) KDM4EGRM6MEN1KMT2AALDH1A1
SCHEMBL6804488 0.75 GRM6 (0.48) KDM4EGRM6MEN1KMT2AMAPT
SCHEMBL6799263 0.74 ESR1 (0.44) KDM4EGRM6MEN1KMT2AMAPT
SCHEMBL6803014 0.70 DAO (0.35) GRM6
SCHEMBL6803705 0.68 CYP3A4 (0.35) BRD4GRM6MEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142976-A1 Pyridylfuran and pyridylthiophene compounds PFIZER INC. 2004-07-22 US disclosed
US-6696470-B2 FOR THERAPY OF ARTHRITIS, ASTHMA, BONE RESORPTION DISEASE, CACHEXIA, CARDIOVASCULAR DISEASE, CEREBRAL MALARIA, CROHN'S DISEASE, DIABETES, FEVER OR MYALGIA DUE TO INFECTION, GOUT, GRAFT VERSUS HOST REACTION, INFLAMMATION OF ORGANS, ETC. PFIZER INC. 2004-02-24 US disclosed
US-20020022729-A1 Pyridylfuran and pyridylthiophene compounds KAWAI AKIYOSHI (JP) 2002-02-21 US disclosed
EP-0853083-B1 Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof PFIZER (US) 2001-09-12 EP disclosed
US-6048880-A THERAPY FOR CYTOKINE SENSITIVE DISEASES PFIZER PHARAMACEUTICALS INC. (JP) 2000-04-11 US disclosed
EP-0853083-A1 Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof PFIZER INC. (US) 1998-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142976-A1 Pyridylfuran and pyridylthiophene compounds MC2R, FCGR2A, OGFR BRD4 1515/4885GPR35 337/4885KDM4E 4616/4885
US-20020022729-A1 Pyridylfuran and pyridylthiophene compounds MC2R, CRHR1, NR3C2 BRD4 1419/4885GPR35 281/4885KDM4E 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.